Advertisement

Oral-Related Disorders

  • Nages Nagaratnam
  • Kujan Nagaratnam
  • Gary Cheuk
Reference work entry

Abstract

The prevalence of awake bruxism is about 20% among the adult population and that of sleep bruxism is 8% of the population. Temporomandibular disorders (TMD) characterise a number of disorders often painful with different causes resulting in dysfunction of joint and/or muscles of mastication. Myofascial pain is estimated that about 25% of the entire population have internal derangement and is usually treated with non-surgical methods. Osteonecrosis of the jaw (ONJ) is characterised by exposure and necrosis of areas of the jaw. The true incidence of ONJ in patients on bisphosphonates (BP) is not known. This review discusses the mechanisms and management of some of the related oral disorders such as bruxism, temporomandibular dysfunction, myofascial pain and osteonecrosis of the jaw.

Keywords

Awake bruxism Sleep bruxism Temporomandibular disorders Myofascial pain Osteonecrosis of the jaw 

References

  1. 1.
    Lavigne GJ, Khoury S, Abe S, Yamaguchi T, Raphael K. Bruxism physiology and pathology: an overview for clinicians. J Oral Rehabil. 2008;35(7):476–94 .CrossRefPubMedGoogle Scholar
  2. 2.
    Cogen JD, Kelly JJ Jr, Loghmanee DA. Sleep bruxism. Pathogenesis and pathophysiology. http://www.medmerits.com/index.php/article/sleep_bruxism/PS accessed 26 May 2016.
  3. 3.
    Lobbezoo F, Naeije M. Bruxism is mainly regulated centrally not peripherally. J Oral Rehabil. 2001;28(12):1085–91.CrossRefPubMedGoogle Scholar
  4. 4.
    Ku BD, Seo SW, Kim E-J, Park KC, Suh M-K, Na DL. P3-024: Diurnal bruxism in advanced Alzheimer’s disease. Alz Dement 2008;4(4Suppl T523.  https://doi.org/10.1016/j.jalz.2008.05.1587.
  5. 5.
    Abe Y, Suganuma T, Ishii M, Yamamoto G, Gunji T, Clark GT, et al. Association of genetic, psychological and behavioural factors with sleep bruxism in a Japanese population. J Sleep Res. 2012;21(3):289–96.CrossRefPubMedGoogle Scholar
  6. 6.
    Goulet JP, Lavigne GJ, Lund JP. Jaw pain prevalence among French speaking Canadians in Quebec and related symptoms of temoporo-mandibular disorders. J Dent Res. 1995;74(11):1738–44.CrossRefPubMedGoogle Scholar
  7. 7.
    Pow EH, Leung KC, McMillan AS. Prevalence of symptoms associated with temporo-mandibular disorders in Hong Kong Chinese. J Orofac Pain. 2001;15(3):228–34.PubMedGoogle Scholar
  8. 8.
    Nekora-Azale A, Evlioglu G, Ordulu M, Issever H. Prevalence of symptoms associated with temporo-mandibular disorders in a Turkish population. J Oral Rehabil. 2006;33(2):61–4.Google Scholar
  9. 9.
    Schmitter M, Rammelsberg P, Hassel A. The prevalence of signs and symptoms of temporo-mandibular disorders in very old subjects. J Oral Rehabil. 2005;32(7):467–73.CrossRefPubMedGoogle Scholar
  10. 10.
    Greene C. Temporo-mandibular disorders in the general population. J Prosthet Dent. 1994;72(5):507–9.CrossRefPubMedGoogle Scholar
  11. 11.
    University of Washington, Diagnostic Radiology Anatomy Module, 2001. Uwmsk.org/tmj/anatomy.html accessed 7 August 2016.
  12. 12.
    Stegenga B. Osteoarthritis of the temporo-mandibular joint organ and its relationship to disc displacement. J Orofac Pain. 2001;15(3):193–205.PubMedGoogle Scholar
  13. 13.
    Mehta NR. Internal temporo-mandibular joint derangement. Merck Manuals Professional version. http://www.merckmanuals.com/professional/dental-disorders/temporomandibular-disorders/internal-temporomandibular-joint-derangement. Accessed 7 August 2016.
  14. 14.
    Ishigaki S, Bessette RW, Maruyama T. The distribution of internal derangement in patients with temporo-mandibular joint dysfunction-prevalence, diagnosis and treatments. Cranio. 1992;10(4):289–96.CrossRefPubMedGoogle Scholar
  15. 15.
    Costa ALF, D’Abreu AD., Cendes F. Temporomandibular joint internal derangement: Association with headache, joint effusion, bruxism and joint pain. Revista Romana de Stomatologie. 2008;LIV (3):193–197.Google Scholar
  16. 16.
    Barkin S, Weinberg S. Internal derangement of temporomandibular joint: The role arthroscopic surgery and arthrocentesis. J Can Dent Assoc. 2000;66:199–203.Google Scholar
  17. 17.
    Tomas X, Pomes J, Berenguer J, Quinto L, Nicolau C, Mercader JR, et al. MR Imaging of temporomandibular joint dysfunction: A pictorial review. Radiographics.2006;26:765–781.CrossRefPubMedGoogle Scholar
  18. 18.
    Farrar WB. Myofascial pain dysfunction syndrome (letter). J Am Dent Assoc. 1981;102:10CrossRefGoogle Scholar
  19. 19.
    Finley JE. Physical medicine and rehabilitation for myofascial pain. http://emedicine.medscape.com/article/313007-overview accessed 7 August 2016.
  20. 20.
    Dorsher PT. Myofascial referred-pain data provide physiologic evidence of acupuncture meridians. J Pain. 2009;10(7):723–31.CrossRefPubMedGoogle Scholar
  21. 21.
    Hoff A, Toth B, Altundag K, Guaneri V, Nooka A, Desronleaux K, et al. Osteonecrosis of the jaw in patients requiring intravenous bisphosphonate therapy. J Clin Oncol. 2006;20: S55.Google Scholar
  22. 22.
    Dimopoulos MA, Kastritis E, Anagnostopoulos A, et al. Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates: evidence of increased risk after treatment with zoledronic acid. Hematologica. 2006;91:968–71.Google Scholar
  23. 23.
    Kahn A. Bisphosphonates associated osteonecrosis of the jaw. Can Fam Physician. 2008;54(7):1019–1021.Google Scholar
  24. 24.
    Huang YF, Chang CT, Muo CH, Tsai CH, Shen YF, Wu CZ. Impact of bisphosphonates –related osteoporosis of the jaw in osteoporotic patients after dental extraction: A population based cohort study. PLOS. One 2015;10(4):e0120756.  https://doi.org/10.1371/journal.pone.0120756.
  25. 25.
    Bamias A, Kastritis E, Bamia C, Moulopoulos LA, Melakopoulos I, Bozas G, et al. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. J Clin Oncol. 2005;23: 8580–87.CrossRefPubMedGoogle Scholar
  26. 26.
    Okabe R, Inaba M, Nakatsuka K, Miki T, Naka K, Moriguchi A, et al. Significance of serum CrossLaps as a predictor of changes in bone mineral density during oestrogen replacement therapy; comparison with serum carboxyterminal telopeptide of type 1 collagen and urinary deoxypyridoline. J Bone Miner Metab. 2004;22(2):127–31.CrossRefPubMedGoogle Scholar
  27. 27.
    Goss A. The CTX test and bisphosphonate-associated ONJ. ADA Dental Therapuetics Committee, 2008.Google Scholar
  28. 28.
    Marx RE. Oral and intravenous bisphosphonate-induced osteonecrosis of the jaws. History, etiology, prevention and treatment. Quintessence Pub Co. 2006Google Scholar
  29. 29.
    Rodrigues CA, Magri LV, Melchior M de O, Mazetto MO. Evaluation of the impact on quality of life of patients with temporomandibular disorders. Rev dor. 2015;16(3):  https://doi.org/10.5935/1806-0013.20150036.

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  • Nages Nagaratnam
    • 1
  • Kujan Nagaratnam
    • 1
  • Gary Cheuk
    • 2
  1. 1.The University of SydneyWestmead Clinical SchoolWestmeadAustralia
  2. 2.Rehabilitation and Aged Care ServiceBlacktown-Mt Druitt HospitalMount DruittAustralia

Personalised recommendations